Vernalis

2017 Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017. http://www.vernalis.com/

, self-sustaining pharmaceutical company. Our strategy to achieve this vision takes the best of what the Company already has and supplements it through in-licensing and acquisition. We are following a three-tier strategy to achieve these goals. http://www.vernalis.com/about-us/vision-and-strategy

One of the UK’s leading commercial stage pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses and our own research activities. The strategy is to: Build a profitable and cash generative business Develop and commercialise low development-risk late-stage products for unmet medical needs in the US Partner all of our NCE drug candidates Leverage our structure- and fragment-based drug discovery expertise via collaborations with leading pharmaceutical companies http://www.vernalis.com/about-us

http://www.ariva.de/vernalis-aktie/kurs GrB